The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1

Lise Barnard; Nikolaos Nikolaou; Carla Louw; Lina Schiffer; Hylton Gibson; Lorna Gilligan; Elena Gangitano; Jacky Snoep; Wiebke Arlt; Jeremy Tomlinson; Karl-Heinz Storbeck

doi:10.1016/j.jsbmb.2020.105724

The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1

Lise Barnard, Nikolaos Nikolaou, Carla Louw, Lina Schiffer, Hylton Gibson, Lorna Gilligan, Elena Gangitano, Jacky Snoep, Wiebke Arlt, Jeremy Tomlinson, Karl-Heinz Storbeck

Metabolism and Systems Research

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

117 Downloads (Pure)

Abstract

Testosterone and its 5α-reduced form, 5α-dihydrotestosterone, were previously thought to represent the only active androgens in humans. However, recent studies have shown that the potent androgen, 11-ketotestosterone, derived from the adrenal androgen precursor, 11β-hydroxyandrostenedione, may in fact serve as the primary androgen in healthy women. Yet, despite recent renewed interest in these steroids, their downstream metabolism has remained undetermined. We therefore set out to investigate the metabolism of 11-ketotestosterone by characterising the 5α- or 5β-reduction commitment step. We show that inactivation of 11-ketotestosterone is predominantly driven by AKR1D1, which efficiently catalyses the 5β-reduction of 11-ketotestosterone, committing it to a metabolic pathway that terminates in 11-ketoetiocholanolone. We demonstrate that 5α-reduction of 11-ketotestosterone is catalysed by SRD5A2, but not SRD5A1, and terminates in 11-ketoandrosterone, but is only responsible for a minority of 11-ketotestosterone inactivation. However, as 11-ketoetiocholanolone is also generated by the metabolism of the glucocorticoid cortisone, 11-ketoandrosterone should be considered a more specific urinary marker of 11-ketotestosterone production.

Original language	English
Article number	105724
Journal	The Journal of Steroid Biochemistry and Molecular Biology
Volume	202
Early online date	3 Jul 2020
DOIs	https://doi.org/10.1016/j.jsbmb.2020.105724
Publication status	Published - Sept 2020

Bibliographical note

Funding Information:
This work was supported by the Wellcome Trust (Investigator Grant WT209492/Z/17/Z , to W.A.), the Academy of Medical Sciences UK (Newton Advanced Fellowship NAF0041002 , to K.-H.S), the National Research Foundation (NRF) of South Africa ( 111622 , to L.B), SARChI DST/NRF grant ( 82813 , to J.S), the European Society of Endocrinology (ESE) (Short-Term Fellowship to E.G), the Medical Research Council, UK (programme grant to J.W.T. MR/P011462/1 ), and the NIHR Oxford Biomedical Research Centre (J.W.T.). W.A. receives support from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant Reference Number BRC-1215-20009). The views expressed are those of the author(s) and not necessarily those of the NIHR UK, the Department of Health and Social Care UK or the NRF of South Africa.

Publisher Copyright:
© 2020 The Authors

Keywords

11-ketoetiocholanolone
11-ketotestosterone
11-oxygenated androgens
steroid 5α-reductase
steroid 5β-reductase
steroid metabolism

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Medicine
Molecular Biology
Endocrinology
Clinical Biochemistry
Cell Biology

Access to Document

10.1016/j.jsbmb.2020.105724Licence: Creative Commons: Attribution (CC BY)

1-s2.0-S0960076020302491-mainFinal published version, 3.57 MBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Dissecting Androgen excess and metabolic dysfunction - an Integrated SYstems approach to PolyCystic Ovary Syndrome (DAISY-PCOS)
Dunn, W., Tino, P., Deeks, J., Arlt, W., Manolopoulos, K., O'Reilly, M. & Afford, S.
THE WELLCOME TRUST
1/04/18 → 1/10/24
Project: Research

Cite this

Barnard, L., Nikolaou, N., Louw, C., Schiffer, L., Gibson, H., Gilligan, L., Gangitano, E., Snoep, J., Arlt, W., Tomlinson, J., & Storbeck, K-H. (2020). The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1. The Journal of Steroid Biochemistry and Molecular Biology, 202, Article 105724. Advance online publication. https://doi.org/10.1016/j.jsbmb.2020.105724

@article{eb14d7b50f7547faa2dff54b901007f3,

title = "The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1",

abstract = "Testosterone and its 5α-reduced form, 5α-dihydrotestosterone, were previously thought to represent the only active androgens in humans. However, recent studies have shown that the potent androgen, 11-ketotestosterone, derived from the adrenal androgen precursor, 11β-hydroxyandrostenedione, may in fact serve as the primary androgen in healthy women. Yet, despite recent renewed interest in these steroids, their downstream metabolism has remained undetermined. We therefore set out to investigate the metabolism of 11-ketotestosterone by characterising the 5α- or 5β-reduction commitment step. We show that inactivation of 11-ketotestosterone is predominantly driven by AKR1D1, which efficiently catalyses the 5β-reduction of 11-ketotestosterone, committing it to a metabolic pathway that terminates in 11-ketoetiocholanolone. We demonstrate that 5α-reduction of 11-ketotestosterone is catalysed by SRD5A2, but not SRD5A1, and terminates in 11-ketoandrosterone, but is only responsible for a minority of 11-ketotestosterone inactivation. However, as 11-ketoetiocholanolone is also generated by the metabolism of the glucocorticoid cortisone, 11-ketoandrosterone should be considered a more specific urinary marker of 11-ketotestosterone production.",

keywords = "11-ketoetiocholanolone, 11-ketotestosterone, 11-oxygenated androgens, steroid 5α-reductase, steroid 5β-reductase, steroid metabolism",

author = "Lise Barnard and Nikolaos Nikolaou and Carla Louw and Lina Schiffer and Hylton Gibson and Lorna Gilligan and Elena Gangitano and Jacky Snoep and Wiebke Arlt and Jeremy Tomlinson and Karl-Heinz Storbeck",

note = "Funding Information: This work was supported by the Wellcome Trust (Investigator Grant WT209492/Z/17/Z , to W.A.), the Academy of Medical Sciences UK (Newton Advanced Fellowship NAF0041002 , to K.-H.S), the National Research Foundation (NRF) of South Africa ( 111622 , to L.B), SARChI DST/NRF grant ( 82813 , to J.S), the European Society of Endocrinology (ESE) (Short-Term Fellowship to E.G), the Medical Research Council, UK (programme grant to J.W.T. MR/P011462/1 ), and the NIHR Oxford Biomedical Research Centre (J.W.T.). W.A. receives support from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant Reference Number BRC-1215-20009). The views expressed are those of the author(s) and not necessarily those of the NIHR UK, the Department of Health and Social Care UK or the NRF of South Africa. Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = sep,

doi = "10.1016/j.jsbmb.2020.105724",

language = "English",

volume = "202",

journal = "The Journal of Steroid Biochemistry and Molecular Biology",

issn = "0960-0760",

publisher = "Elsevier",

}

TY - JOUR

T1 - The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1

AU - Barnard, Lise

AU - Nikolaou, Nikolaos

AU - Louw, Carla

AU - Schiffer, Lina

AU - Gibson, Hylton

AU - Gilligan, Lorna

AU - Gangitano, Elena

AU - Snoep, Jacky

AU - Arlt, Wiebke

AU - Tomlinson, Jeremy

AU - Storbeck, Karl-Heinz

N1 - Funding Information: This work was supported by the Wellcome Trust (Investigator Grant WT209492/Z/17/Z , to W.A.), the Academy of Medical Sciences UK (Newton Advanced Fellowship NAF0041002 , to K.-H.S), the National Research Foundation (NRF) of South Africa ( 111622 , to L.B), SARChI DST/NRF grant ( 82813 , to J.S), the European Society of Endocrinology (ESE) (Short-Term Fellowship to E.G), the Medical Research Council, UK (programme grant to J.W.T. MR/P011462/1 ), and the NIHR Oxford Biomedical Research Centre (J.W.T.). W.A. receives support from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant Reference Number BRC-1215-20009). The views expressed are those of the author(s) and not necessarily those of the NIHR UK, the Department of Health and Social Care UK or the NRF of South Africa. Publisher Copyright: © 2020 The Authors

PY - 2020/9

Y1 - 2020/9

N2 - Testosterone and its 5α-reduced form, 5α-dihydrotestosterone, were previously thought to represent the only active androgens in humans. However, recent studies have shown that the potent androgen, 11-ketotestosterone, derived from the adrenal androgen precursor, 11β-hydroxyandrostenedione, may in fact serve as the primary androgen in healthy women. Yet, despite recent renewed interest in these steroids, their downstream metabolism has remained undetermined. We therefore set out to investigate the metabolism of 11-ketotestosterone by characterising the 5α- or 5β-reduction commitment step. We show that inactivation of 11-ketotestosterone is predominantly driven by AKR1D1, which efficiently catalyses the 5β-reduction of 11-ketotestosterone, committing it to a metabolic pathway that terminates in 11-ketoetiocholanolone. We demonstrate that 5α-reduction of 11-ketotestosterone is catalysed by SRD5A2, but not SRD5A1, and terminates in 11-ketoandrosterone, but is only responsible for a minority of 11-ketotestosterone inactivation. However, as 11-ketoetiocholanolone is also generated by the metabolism of the glucocorticoid cortisone, 11-ketoandrosterone should be considered a more specific urinary marker of 11-ketotestosterone production.

AB - Testosterone and its 5α-reduced form, 5α-dihydrotestosterone, were previously thought to represent the only active androgens in humans. However, recent studies have shown that the potent androgen, 11-ketotestosterone, derived from the adrenal androgen precursor, 11β-hydroxyandrostenedione, may in fact serve as the primary androgen in healthy women. Yet, despite recent renewed interest in these steroids, their downstream metabolism has remained undetermined. We therefore set out to investigate the metabolism of 11-ketotestosterone by characterising the 5α- or 5β-reduction commitment step. We show that inactivation of 11-ketotestosterone is predominantly driven by AKR1D1, which efficiently catalyses the 5β-reduction of 11-ketotestosterone, committing it to a metabolic pathway that terminates in 11-ketoetiocholanolone. We demonstrate that 5α-reduction of 11-ketotestosterone is catalysed by SRD5A2, but not SRD5A1, and terminates in 11-ketoandrosterone, but is only responsible for a minority of 11-ketotestosterone inactivation. However, as 11-ketoetiocholanolone is also generated by the metabolism of the glucocorticoid cortisone, 11-ketoandrosterone should be considered a more specific urinary marker of 11-ketotestosterone production.

KW - 11-ketoetiocholanolone

KW - 11-ketotestosterone

KW - 11-oxygenated androgens

KW - steroid 5α-reductase

KW - steroid 5β-reductase

KW - steroid metabolism

UR - http://www.scopus.com/inward/record.url?scp=85087996769&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2020.105724

DO - 10.1016/j.jsbmb.2020.105724

M3 - Article

C2 - 32629108

SN - 0960-0760

VL - 202

JO - The Journal of Steroid Biochemistry and Molecular Biology

JF - The Journal of Steroid Biochemistry and Molecular Biology

M1 - 105724

ER -

The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Projects

Dissecting Androgen excess and metabolic dysfunction - an Integrated SYstems approach to PolyCystic Ovary Syndrome (DAISY-PCOS)

Cite this